Patent ID: 8362063

Claim:
A method of treating a disorder or a disease in a subject mediated by MMP-2, and/or MMP-8, and/or MMP-9, and/or MMP-12 and/or MMP-13, comprising: administering to the subject a therapeutically effective amount of a compound of formula (III) wherein R′ 1 is selected from hydrogen, alkyl, cycloakyl, R 5 C(O)—, R 6 SO 2 —, (R 7 )NH—C(O)—, and (R 8 )(R 9 )N—, aryl, heteroaryl, heterocycloalkyl, said aryl, heteroaryl, and heterocycloalkyl are optionally substituted by one or two substituents selected from alkyl-SO 2 —, alkyl-C(O)—, heterocycloalkyl-alkyl-, alkyl-alkoxy-, alkoxy-, alkyl, aryl, cycloalkyl, halo, alkoxy-alkyl-, alkyl-O—C(O)—, cycloalkyl-alkyl-, dialkylamino-alkoxy-, and dialkylamino-alkyl-; wherein R 5 , R 6 , R 7 , R 8 and R 9 are independently alkyl or aryl, each of which is optionally substituted by one to five substituents selected from the group consisting of (C 1 -C 7 ) alkyl, halo, hydroxy, (C 1 -C 7 ) alkoxy, and aryl; R 2 and R 3 are hydrogen; X is selected from hydrogen, cyano, halogen, nitro, alkyl-S—, alkyl-SO—, alkyl-SO 2 —, H 2 N—SO 2 —, R 5 —C(O)—, alkyl, and R 4 —O, wherein R 4 and R 5 are independently alkyl or aryl each of which is optionally substituted by substituents selected from the group consisting of (C 1 -C 7 ) alkyl, halo, hydroxy, (C 1 -C 7 ) alkoxy, and aryl; Y is C or N; or a pharmaceutically acceptable salt thereof, or an optical isomer thereof; or a mixture of optical isomers; wherein the disorder or disease is selected from Alport syndrome, asthma, rhinitis, chronic obstructive pulmonary diseases (COPD), arthritis, atherosclerosis, cancer metastasis, loosening of hip joint replacements, periodontal disease, and fibrotic disease of the lung.